- Home
- BMBL vs REPL Comparison
BMBL vs REPL Comparison
Compare BMBL & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMBL
- REPL
- Stock Information
- Founded
- BMBL 2014
- REPL 2015
- Country
- BMBL United States
- REPL United States
- Employees
- BMBL N/A
- REPL N/A
- Industry
- BMBL Computer Software: Prepackaged Software
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- BMBL Technology
- REPL Health Care
- Exchange
- BMBL Nasdaq
- REPL Nasdaq
- Market Cap
- BMBL 756.3M
- REPL 690.7M
- IPO Year
- BMBL 2021
- REPL 2018
- Fundamental
- Price
- BMBL $6.65
- REPL $11.56
- Analyst Decision
- BMBL Buy
- REPL Strong Buy
- Analyst Count
- BMBL 17
- REPL 5
- Target Price
- BMBL $8.61
- REPL $24.00
- AVG Volume (30 Days)
- BMBL 2.7M
- REPL 983.7K
- Earning Date
- BMBL 11-05-2024
- REPL 11-05-2024
- Dividend Yield
- BMBL N/A
- REPL N/A
- EPS Growth
- BMBL N/A
- REPL N/A
- EPS
- BMBL 0.31
- REPL N/A
- Revenue
- BMBL $1,085,537,000.00
- REPL N/A
- Revenue This Year
- BMBL $3.63
- REPL N/A
- Revenue Next Year
- BMBL $0.37
- REPL $511.76
- P/E Ratio
- BMBL $21.53
- REPL N/A
- Revenue Growth
- BMBL 11.11
- REPL N/A
- 52 Week Low
- BMBL $4.80
- REPL $4.92
- 52 Week High
- BMBL $15.90
- REPL $16.70
- Technical
- Relative Strength Index (RSI)
- BMBL 53.09
- REPL 57.71
- Support Level
- BMBL $6.28
- REPL $10.69
- Resistance Level
- BMBL $6.67
- REPL $12.86
- Average True Range (ATR)
- BMBL 0.28
- REPL 0.72
- MACD
- BMBL 0.09
- REPL 0.05
- Stochastic Oscillator
- BMBL 81.77
- REPL 49.22
About BMBL Bumble Inc.
Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.